Skip to main content
Premium Trial:

Request an Annual Quote

Haystack Oncology: Bert Vogelstein, Diamantis Xylas, George Petrocheilos, Isaac Ro

Bert Vogelstein, Diamantis Xylas, George Petrocheilos, and Isaac Ro have joined the board of directors of Johns Hopkins University spinout Haystack Oncology in connection with the firm's recent Series A financing.

Vogelstein is codirector of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center and a scientific cofounder of Haystack, Exact Sciences, and Thriver Earlier Detection. Xylas, who will be an observer on Haystack's board, is head of research; and Petrocheilos is cofounder and managing partner at Catalio Capital Management, Haystack's lead investor. Ro, who will chair Haystack's board, is the former CFO of Thrive Earlier Detection (acquired by Exact Sciences in 2020) and the former CFO of Sema4.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.